Spectrum of immune-mediated necrotizing myopathies and their treatments

Current Opinion in Rheumatology

Volumn 28, Issue 6, 2016, Pages 619-624

  Pinal Fernandez, Iago ^a   Mammen, Andrew L ^a,b  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 hydroxy 3 methylglutaryl CoA reductase; Autoantibody; Autoimmunity; Immune mediated necrotizing myopathy; Myositis; Signal recognition particle

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; SIGNAL RECOGNITION PARTICLE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A; ACYL COENZYME A; AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; REVIEW; AUTOIMMUNE DISEASES; BIOPSY; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; NECROSIS; PATHOLOGY; SKELETAL MUSCLE;

ACYL COENZYME A; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOPSY; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MYOSITIS; NECROSIS; SIGNAL RECOGNITION PARTICLE;

EID: 84986237587     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000335     Document Type: Review

References (38)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344-347.
2. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337-345.
3. Pinal-Fernandez I, Parks C, Werner JL, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 2016. [Epub ahead of print]
4. Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with antisignal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015; 10:61.
5. Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016. [Epub ahead of print]
6. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neu-rosurg Psychiatry 2002; 73:420-428.
7. Kao AH, Lacomis D, Lucas M, et al. Anti-signal recognition particle autoanti-body in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-215.
8. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635-1638.
9. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33:1361-1370.
10. Wang L, Liu L, Hao H, et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neu-romuscul Disord 2014; 24:335-341.
11. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92:223-243.
12. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328-1334.
13. Lahouti AH, Brodsky RA, Christopher-Stine L. Idiopathic inflammatory myo-pathy treated with high-dose immunoablative F cyclophosphamide-a long-term follow-up study. JAMA Neurol 2015; 72:1205-1206.
14. O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A,-B,-Cw,-DRB1, and-DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85:111-127.
15. Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139:2131-2135.
16. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41:936-939.
17. Rojana-udomsart A, Mitrpant C, Bundell C, et al. Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM). J Neuroimmunol 2013; 264:65-70.
18. Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:1961-1971.
19. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757-2766.
20. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713-721.
21. Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neu-roinflamm 2015; 2:e124.
22. Chung T, Christopher-Stine L, Paik JJ, et al. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 2015; 52:189-195.
23. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1 ∗11:01 in antihydroxymethylglutaryl-coenzyme A reductase-asso-ciated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64:1233-1237.
24. Limaye V, Bundell C, Hollingsworth P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015; 52:196-203.
25. Klein M, Mann H, Plestilova L, et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology (Oxford) 2015; 54:2010-2014.
26. Basharat P, Lahouti AH, Paik JJ, et al. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol 2016; 68:234-235.
27. Ge Y, Lu X, Peng Q, et al. Clinical characteristics of anti3-hydroxy-3-methyl-glutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies. PLoS One 2015; 10:e0141616.
28. Alarcon J, Aguila S, Arancibia-Avila P, et al. Production and purification of statins from Pleurotus ostreatus (Basidiomycetes) strains. Z Naturforsch C 2003; 58:62-64.
29. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
30. Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005; 12:121-131.
31. Chushi L, Wei W, Kangkang X, et al. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene 2016; 587:42-47.
32. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64:4087-4093.
33. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150-157.
34. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglu-taryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64:269-272.
35. Floyd JS, Brody JA, Tiniakou E, et al. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle Nerve 2016; 54:142-144.
36. Mammen AL, Tiniakou E. Intravenous immune globulin for statintriggered autoimmune myopathy. N Engl J Med 2015; 373:1680-1682.
37. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, et al. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015; 42:1448-1454.
38. Paik JJ, Wigley FM, Lloyd TE, et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken) 2015; 67:1416-1425.